<?xml version="1.0" encoding="UTF-8"?>
<svg height="870.031005859375" width="672.0029907226562" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <path d=" M 0.05999799817800522 826.072021484375 L 22.619997024536133 826.072021484375 L 22.619997024536133 826.35546875 L 0.05999799817800522 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 837.4110107421875 L 33.959449768066406 837.4110107421875 L 33.959449768066406 860.031005859375 L 33.67599868774414 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 837.4110107421875 L 628.2703857421875 837.4110107421875 L 628.2703857421875 860.031005859375 L 627.9869995117188 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 826.072021484375 L 662.0029907226562 826.072021484375 L 662.0029907226562 826.35546875 L 639.3259887695312 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 33.731998443603516 L 662.0029907226562 33.731998443603516 L 662.0029907226562 34.015480041503906 L 639.3259887695312 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 0.0 L 628.2703857421875 0.0 L 628.2703857421875 22.677000045776367 L 627.9869995117188 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 0.0 L 33.959449768066406 0.0 L 33.959449768066406 22.677000045776367 L 33.67599868774414 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 0.05999799817800522 33.731998443603516 L 22.619997024536133 33.731998443603516 L 22.619997024536133 34.015480041503906 L 0.05999799817800522 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="80.844,86.726,91.675,95.593,98.588,101.009,103.43,110.801,113.221,116.109,120.592,123.479,125.9,130.849,135.799,139.251,142.297,147.247,150.13400000000001,153.126,158.075,163.025,166.477,169.453,172.905,175.792,180.741,185.691,190.174,193.206,195.627,200.577,204.495,206.916,211.865,216.814,220.732,223.706,226.593,231.543,235.461,238.502,241.389,246.339,248.76,251.181,256.13,263.034,265.455,270.404,274.887" y="357.569" svg_rhmargin="277.308" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">The limitations of our study include the following:</text>
  <text x="71.887,74.774,79.723,82.61,86.003,91.885,96.835,100.753,107.036,111.985,116.934,124.305,129.254,133.172,136.624,142.921,147.871,150.758,157.094,159.982,164.931,168.84900000000002,175.122,177.543,182.492,186.411,188.832,193.781,198.73,202.649,207.598,213.899,220.336,226.774,232.656,236.108,242.414,247.364,250.251,256.531,259.983,262.404,265.856,269.774,274.723,278.175,283.125,288.074,292.557,295.444,299.362,305.682,308.569,313.519" y="374.009" svg_rhmargin="316.971" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(1) The number of the included RCTs of risedronate for</text>
  <text x="86.003,90.953,94.405,98.323,102.806,106.724,111.674,114.561,116.982,121.931,126.414,129.371,134.321,139.27,144.22,148.138,151.028,153.449,158.398,161.85,165.302,168.149,172.632,175.519,178.406,182.325,185.777,188.728,194.609,202.078,208.516,211.404,218.308,222.791,226.243,229.148,231.569,233.99,241.361,243.781,246.669,250.587,255.536,257.957,260.839,269.805,274.755,278.207,281.094,284.026,288.975,291.862,294.741,301.178,307.616,313.498" y="384.951" svg_rhmargin="316.95" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">preventing bone loss after THA was limited. Most of RCTs</text>
  <text x="86.003,88.89,93.84,97.758,102.708,106.16,110.078,115.027,121.435,126.385,131.334,137.649,144.553,149.502,155.847,160.797,164.249,170.644,177.548,182.497,188.842,193.792,196.213,199.665,204.614,209.563,214.513,217.965,222.914,227.864,232.813,237.762,242.246,245.133,249.051,252.503,258.856,261.743,266.692,270.144,276.544,281.493,284.945,288.863,293.346,297.265,302.214,305.101,307.522,312.471" y="395.892" svg_rhmargin="316.954" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">focused on G1 or G2 bisphosphonates for preventing</text>
  <text x="86.003,90.953,95.902,100.851,104.769,108.51,110.931,115.88,119.332,122.78399999999999,126.481,130.964,133.851,136.738,140.656,144.108,147.854,153.736,161.205,167.642,170.063,173.762,178.711,183.661,186.548,191.497,194.949,198.86700000000002,202.618,206.07,208.957,213.907,218.856,221.277,225.195,228.647,232.381,235.833,240.782,245.732,250.681,253.102,258.051,261.747,266.697,270.615,274.333,277.22,282.17,286.088,291.038,294.49,298.408,303.357,307.044,311.994" y="406.891" svg_rhmargin="316.943" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">bone loss after THA. Future studies should be focused on</text>
  <text x="86.003,88.89,93.84,97.75800000000001,100.687,104.605,109.554,116.924,121.874,126.357,129.809,132.23,135.682,140.631,145.58,148.477,153.426,157.345,160.232,167.136,171.054,174.972,179.92100000000002,182.889,189.793,194.742,197.163,204.067,209.01600000000002,211.914,216.864,219.285,222.737,227.686,232.635,237.585,241.037,245.986,250.936,255.885,260.835,265.318,268.205,272.123,275.575,278.469,282.953,286.871,290.323,293.775,298.724,302.176,305.115,312.019" y="417.833" svg_rhmargin="316.968" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">the comparison between G1/G2 bisphosphonates versus G3</text>
  <text x="86.003,90.953,93.374,96.826,101.775,106.724,111.674,115.126,120.075,125.025,129.974,134.923,139.407,142.294,146.212,149.664,152.729,155.616,160.565,164.017,167.015,172.897,180.366,186.804,189.748,194.697,199.18,202.068,204.488,208.407,213.356,216.243,219.695" y="428.775" svg_rhmargin="222.116" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">bisphosphonates for THA patients.</text>
  <text x="71.887,74.774,79.723,82.61,86.003,91.885,96.835,100.753,102.614,105.501,110.451,112.872,115.293,120.242,127.146,130.033,134.983,139.93200000000002,141.788,146.737,149.624,151.426,154.313,159.262,163.18,165.032,167.453,172.403,176.321,178.742,183.691,188.641,192.559,197.508,199.33,205.768,212.206,218.088,221.54,223.367,226.819,231.302,236.252,240.735,244.653,249.602,251.429,254.316,257.768,262.717,270.087,271.951,276.90000000000003,278.697,286.067,291.017,295.966,298.853,303.803,307.255,309.14,312.028" y="439.716" svg_rhmargin="316.977" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(2) The follow-up of the included RCTs ranged from 6 months to</text>
  <text x="86.003,90.952,94.621,99.104,103.022,107.505,110.957,114.409,116.83000000000001,120.472,124.955,129.904,134.853,138.499,145.869,150.819,154.271,158.189,161.856,165.308,168.196,173.145,178.094,180.515,184.434,187.886,191.563,195.015,199.964,204.913,209.863,212.284,217.233,220.872,225.821,229.739,233.4,236.287,241.237,245.155,250.105,253.557,257.475,262.42400000000004,266.055,271.004,275.95300000000003,279.605,282.025,286.975,291.924,296.407,299.295,302.182,306.1,309.552" y="450.714" svg_rhmargin="316.922" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">4 years, and more studies should be focused on long-term</text>
  <text x="86.003,89.922" y="461.656" svg_rhmargin="92.809" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ef</text>
  <text x="92.863" y="461.656" svg_rhmargin="97.812" style="fill:#171615;font-family:BPGNFI+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="97.796,101.714,106.197,110.115,114.598,117.581,122.53,125.417,128.409,131.861,134.282,137.734,141.653,146.602,150.054,155.003,159.953,164.436,167.323,171.241,174.272,177.159,182.109,185.561,188.558,193.507,198.457,203.406,207.324,210.327,212.748,217.698,221.15,224.602,227.618,230.039,234.988,237.936,243.818,251.287,257.725,260.726,265.675,270.159,273.046,275.467,279.385,284.334,287.221,290.673" y="461.656" svg_rhmargin="293.094" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cacy of risedronate for bone loss in THA patients.</text>
  <text x="71.887,74.774,79.723,82.61,86.003,91.885,96.368,101.318,105.236,107.943,112.892,115.779,118.487,123.437,126.889,131.838,135.29,138.177,143.127,147.045,150.497,152.918,156.37,159.135,166.039,170.522,173.974,176.653,181.602,186.551,189.438,192.129,197.079,202.028,206.511,211.461,213.882,221.252,226.201,231.151,234.603,237.369,239.79,244.739,247.403,251.886,254.307,256.728,259.478,264.427,267.314,270.022,272.909,277.859,281.777,284.479,286.9,291.849,295.767,298.188,303.138,308.087,312.005" y="472.597" svg_rhmargin="316.954" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(3) Type of prosthesis was not unanimous in all of the included</text>
  <text x="86.003,92.441,98.879,104.761,108.213,110.634,113.838,121.209,126.158,129.61,133.52800000000002,136.685,140.137,143.024,147.974,152.923,155.344,159.262,162.714,165.938,169.39,174.339,179.289,184.238,186.659,191.608,194.737,199.686,203.604,206.813,211.296,216.245,221.195,224.647,228.565,232.017,235.469,239.387,244.336,247.517,250.969,255.918,260.868,265.351,268.803,273.752,278.702,283.651,286.804,291.287,296.236,300.719,303.14,307.623,311.075,313.496" y="483.595" svg_rhmargin="316.948" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">RCTs; more studies should be addressed subgroup analysis</text>
  <text x="86.003,89.455,91.876,95.328,99.247,104.196,107.648,112.597,117.547,122.03,124.917,128.835,131.866,134.753,139.702,143.154,146.152,151.101,153.522,156.409,159.297,163.215,166.667,170.585,175.534,178.421,181.47,184.357,188.84,193.79,197.708,200.689,205.638,208.525,211.517,216.467,219.919,224.868,228.32,231.207,236.157,240.075,243.527,245.948,249.4,252.448,257.398,260.285,263.277,269.159,276.628,283.066" y="494.537" svg_rhmargin="285.487" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">risedronate for different type of prosthesis of THA.</text>
  <text x="71.887,74.774,79.723,82.61,86.003,92.907,97.857,101.309,105.227,110.721,115.67,118.557,123.986,127.438,129.859,133.311,137.23,142.179,145.631,150.58,155.53,160.013,162.9,166.818,172.287,179.191,183.674,187.126,192.582,197.532,199.952,202.84,205.727,209.645,213.097,217.015,221.965,224.852,230.338,235.288,239.206,242.093,248.997,252.915,256.834,261.783,267.245,270.132,275.081,278.999,284.479,286.9,291.849,295.767,298.188,303.138,308.087,312.005" y="505.479" svg_rhmargin="316.954" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">(4) Dose of risedronate was different between the included</text>
  <text x="86.003,89.455,92.342,97.292,102.241,104.662,108.58,112.032,114.453,116.786,120.238,125.187,127.445,134.815,139.764,143.216,147.13400000000001,149.384,152.836,155.723,160.673,165.622,168.043,171.961,175.413,177.729,181.181,186.131,191.08,196.03,198.451,203.4,205.678,210.628,214.546,216.79,221.273,223.694,228.177,232.096,237.04500000000002,239.297,243.78,248.263,252.746,255.167,257.588,262.071,267.02,269.441,273.359,275.693,280.642,285.125,288.012,292.495,294.741,299.224,304.173,309.123,314.072" y="516.477" svg_rhmargin="316.959" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">studies, so more studies should be given available data about</text>
  <text x="86.003,88.89,93.84,97.75800000000001,99.949,104.899,109.848,112.735,115.156,122.527,127.01,129.431,131.583,136.532,141.481,144.933,148.851,150.971,155.921,158.808,160.949,164.401,166.822,170.274,174.192,179.142,182.594,187.543,192.492,196.976,199.863,203.781,205.962,208.849,213.798,217.25,219.398,224.347,227.799,231.717,236.201,240.119,245.068,247.955,250.376,255.326,259.80899999999997,261.972,266.922,271.871,276.821,280.73900000000003,282.892,285.313,290.262,293.714,297.166,299.332,303.815,306.703,309.59,313.508" y="527.418" svg_rhmargin="316.96" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">the optimal dose of risedronate for preventing bone loss after</text>
  <text x="86.003,91.885,99.354,105.792" y="538.36" svg_rhmargin="108.213" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">THA.</text>
  <text x="71.887,77.802,80.75500000000001,85.493,92.591,98.308,104.223,109.741,112.495,118.411,123.635,126.389,132.106,138.021" y="570.5070000000001" svg_rhmargin="143.245" style="fill:#171615;font-family:BPGNDO+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">5. Conclusions</text>
  <text x="71.887,74.774,79.723,82.374,86.293,91.242,96.192,100.11,102.531,107.48,110.932,113.353,118.302,123.252,125.673,128.407,133.357,136.809,141.292,143.713,146.379,149.831,152.252,155.704,159.622,164.571,168.023,172.973,177.922,182.405,185.292,189.21,191.901,196.851,201.334,204.786,207.435,211.918,216.86700000000002,219.51,223.429,226.316,229.203,233.121,237.04,239.927,242.641,247.59,252.53900000000002,255.169,258.057,263.006,266.924,269.626,274.575,278.027,281.946,285.398,289.316,292.768,297.251,301.734,304.621,307.042,311.992" y="586.438" svg_rhmargin="316.941" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">In conclusion, oral risedronate has an effect on the preservation</text>
  <text x="71.887,76.836,79.723,82.035,86.984,90.902,94.354,96.775,101.725,105.177,110.126,113.578,116.465,121.415,125.333,128.22,130.641,134.559,136.911,142.327,151.293,158.197,160.495,162.916,167.865,170.133,175.082,178.534,183.484,188.433,190.854,198.224,202.708,205.129,207.436,210.888,214.806,219.289,221.71,226.659,231.609,235.061,237.369,240.256,247.16,250.612,255.561,259.48,264.42900000000003,266.735,270.653,275.603,280.552,284.47,287.922,290.262,295.211,297.632,299.9,304.849,307.27,309.594,314.543" y="597.379" svg_rhmargin="316.964" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">of periprosthetic BMD in proximal regions (Gruen zones 1, 2, 3,</text>
  <text x="71.887,76.37,81.319,86.268,88.213,93.163,96.05,97.964,102.447,105.334,107.261,112.21,114.121,121.492,126.441,131.391,134.278,139.227,142.679,144.621,149.104,151.992,154.879,158.797,162.249,164.179,170.061,177.53,183.968,186.38899999999998,188.33,197.296,201.215,205.698,210.647,217.551,222.501,224.922,227.343,231.261,233.682,235.667,240.616,244.068,248.551,250.97199999999998,252.901,256.353,258.774,262.226,266.144,271.094,274.546,279.495,284.444,288.928,291.815,295.733,297.687,302.636,307.119,310.571,312.483" y="608.377" svg_rhmargin="316.966" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">and 7) at 3 months after THA. Meanwhile, oral risedronate has a</text>
  <text x="71.887,76.836,80.754,85.704" y="619.319" svg_rhmargin="89.622" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">bene</text>
  <text x="89.632" y="619.319" svg_rhmargin="94.581" style="fill:#171615;font-family:BPGNFI+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="94.564,98.482,100.903,105.386,107.807,109.758,113.21,118.159,120.58,124.498,126.425,131.374,136.323,138.217,141.104,146.053,149.971,151.879,156.829,160.281,164.199,167.651,171.569,175.021,179.505,183.988,186.875,189.296,194.245,199.19400000000002,201.144,206.093,208.98,210.895,215.844,219.762,223.214,225.635,230.585,234.037,238.986,242.438,245.325,250.275,254.193,257.08,259.501,263.419,265.375,270.791,279.757,286.661,288.562,290.983,295.932,297.859,302.342,304.763,307.18399999999997,309.14,314.09" y="619.319" svg_rhmargin="316.977" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cial role on the preservation of periprosthetic BMD in all of</text>
  <text x="71.887,74.774,79.723,83.641,86.91,90.362,94.28,98.763,101.184,106.133,111.083,114.535,117.749,122.232,125.119,128.351,133.3,136.571,141.054,146.004,150.953,154.146,159.096,164.04500000000002,167.299,174.669,179.619,184.568,187.455,192.404,195.856,199.102,203.585,206.473,209.36,213.278,216.73,219.965,225.847,233.316,239.754,242.17499999999998,245.42,252.324,257.273,261.19100000000003,264.468,267.355,272.30400000000003,275.523,278.41,283.36,287.278,290.546,292.967,295.388,302.758,305.179,308.066,311.984" y="630.261" svg_rhmargin="316.933" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">the regions at 6 and 12 months after THA. Due to the limited</text>
  <text x="71.887,74.308,79.257,83.175,85.596,90.545,95.495,99.413,104.362,108.509,111.961,114.849,119.798,124.747,127.168,131.087,134.539,138.669,143.153,148.102,153.05100000000002,157.207,160.659,165.609,170.558,174.01,176.897,180.815,185.765,193.135,195.556,200.505,204.988,209.136,214.086,216.973,221.098,223.986,228.935,231.356,234.808,238.957,246.327,250.245,253.132,257.615,260.503,264.986,269.935,274.418,276.839,281.322,284.774,287.195,290.647,293.068,297.235,304.605,309.555,313.007" y="641.259" svg_rhmargin="316.925" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">included studies and shortcoming of this meta-analysis, more</text>
  <text x="71.887,76.836,79.257,83.74,88.689,91.577,96.526,101.475,105.959,108.379,110.8,113.687,118.17,121.888,128.326,134.764,140.646,144.09799999999998,147.796,154.7,158.618,162.071,165.989,169.679,173.131,176.018,178.439,180.86,183.281,186.97,191.919,195.838,199.756,204.705,208.624,213.573,217.299,220.186,225.13500000000002,228.808,231.229,236.178,240.096,245.046,247.933,250.354,253.241,257.724,261.405,264.292,269.241,273.159,276.881,280.8" y="652.2" svg_rhmargin="283.687" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">high-quality RCTs were still needed to identify the ef</text>
  <text x="283.692" y="652.2" svg_rhmargin="288.641" style="fill:#171615;font-family:BPGNFI+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="288.625,292.543,297.026,300.944,305.427,309.147,314.096" y="652.2" svg_rhmargin="316.983" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cacy of</text>
  <text x="71.887,75.339,77.76,81.212,85.13,90.079,93.531,98.481,103.43,107.913,110.8,114.718,117.749,120.636,125.586,129.038,132.035,136.985,141.934,146.883,150.80100000000002,153.805,156.225,161.175,164.627,168.079,171.039,173.46,178.40900000000002,181.414,187.295,194.764,201.202" y="663.142" svg_rhmargin="203.623" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">risedronate for bone loss in THA.</text>
  <text x="71.887,78.483,84.399,88.043,93.958,99.675,103.612,106.752,112.27,117.987,123.902,127.546,131.483,134.237,140.153,146.068,149.712,152.466,158.183,164.098" y="691.773" svg_rhmargin="169.322" style="fill:#171615;font-family:BPGNDO+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">Author contributions</text>
  <text svg_rhmargin="128.087" x="71.887,78.791,83.274,86.161,90.644,93.656,97.574,102.524,105.976,110.459,113.346,115.767,120.716,125.666,128.087" y="707.761" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Data curation: </text>
  <text x="131.074,134.526,136.947,141.896,146.379,149.385,153.868,158.818" y="707.761" svg_rhmargin="161.239" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Jing Su.</text>
  <text svg_rhmargin="126.213" x="71.887,80.853,84.771,87.658,92.608,97.557,102.507,107.456,109.877,114.826,119.309,123.792,126.21300000000001" y="718.702" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Methodology: </text>
  <text svg_rhmargin="158.836" x="129.204,135.641,138.06199999999998,141.109,150.075,153.994,156.415,158.83599999999998" y="357.568" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Yi Wei. </text>
  <text svg_rhmargin="368.323" x="331.938,336.421,341.371,344.258,347.145,354.049,358.532,361.984,365.902,368.323" y="357.568" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Software: </text>
  <text x="371.34,378.244,380.664,385.148,390.09700000000004,393.052,402.019,404.44,409.389,413.872,416.862,422.278,424.699" y="357.568" svg_rhmargin="427.12" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Xiao Ming Li.</text>
  <text svg_rhmargin="378.787" x="331.938,336.421,341.371,346.32,350.238,353.69,358.173,360.594,364.046,366.467,371.417,376.366,378.787" y="368.509" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Supervision: </text>
  <text x="381.771,388.675,391.096,395.579,400.528,403.54,412.506,414.927,419.877,424.36,427.35,432.766,435.187,437.608,440.616,447.054,451.537,456.486,459.373,464.323,466.744,471.693,476.176,479.166,486.07,488.49,492.974,497.923,500.344,503.373,510.842,515.791,520.274,522.695,525.582,532.486,536.969,541.919,546.4019999999999,549.406,554.821,557.242,562.192" y="368.509" svg_rhmargin="564.613" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Xiao Ming Li, Yan-Ping Diao, Huai-Gang Liu.</text>
  <text svg_rhmargin="374.761" x="331.938,338.376,342.859,345.28,347.701,352.65,357.133,360.02,362.441,367.391,372.34,374.76099999999997" y="379.451" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Validation: </text>
  <text x="377.746,384.184,388.667,393.616,396.503,401.453,403.874,408.823,413.306,416.352,423.256,425.677,430.16,435.11,437.531,440.503,447.972,452.921,457.404,459.825,462.712,469.616,474.1,479.049,483.532,486.536,491.952,494.372,499.322" y="379.451" svg_rhmargin="501.743" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Yan-Ping Diao, Huai-Gang Liu.</text>
  <text svg_rhmargin="384.552" x="331.938,338.376,340.797,344.249,349.198,353.681,356.102,358.523,362.441,366.924,369.812,372.233,377.182,382.131,384.55199999999996" y="390.449" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Visualization: </text>
  <text x="387.554,392.97,395.391,399.874,404.823,409.306,412.328,418.766,423.715,428.198,433.148,437.631" y="390.449" svg_rhmargin="440.052" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Liang Zhang.</text>
  <text svg_rhmargin="361.518" x="331.938,340.904,344.356,346.777,349.664,352.085,357.035,361.51800000000003" y="401.39" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="368.963" x="364.48,368.963" y="401.39" style="fill:#171615;font-family:BPHKHJ+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="425.64" x="371.964,376.913,380.365,382.786,387.269,389.69,394.639,399.122,401.543,404.561,409.51,412.962,417.445,420.332,423.219,425.64" y="401.39" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">original draft: </text>
  <text x="428.657,432.109,434.53,439.479,443.962,446.968,451.451,456.4,458.82099999999997,461.821,468.259,470.68,473.67,482.636,486.555,488.976" y="401.39" svg_rhmargin="491.397" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Jing Su, Yi Wei.</text>
  <text svg_rhmargin="361.518" x="331.938,340.904,344.356,346.777,349.664,352.085,357.035,361.51800000000003" y="412.332" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="368.963" x="364.48,368.963" y="412.332" style="fill:#171615;font-family:BPHKHJ+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="439.928" x="371.964,375.416,379.334,383.817,386.238,390.156,397.06,400.083,408.48400000000004,411.478,415.396,420.346,422.767,425.654,428.075,433.024,437.507,439.928" y="412.332" style="fill:#171615;font-family:BPHKHI+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">review &amp; editing: </text>
  <text x="442.944,448.359,450.78,455.263,460.213,464.696,467.717,474.155,479.105,483.588,488.537,493.02" y="412.332" svg_rhmargin="495.441" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Liang Zhang.</text>
  <text x="331.937,338.732,344.449,347.894,353.611,357.548,363.265,369.18,374.698,380.415" y="435.521" svg_rhmargin="385.639" style="fill:#171615;font-family:BPGNDO+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">References</text>
  <text x="336.189,338.595,342.719,345.125,348.434,353.798,357.923,361.659,365.784,368.898,374.651,376.668,379.726,385.95,390.075,393.161,398.915,400.932,403.989,410.131,412.149,416.274,419.352,422.229,424.246,427.289,430.554,432.96,436.019,439.755,441.772,443.789,446.903,451.416,453.822,456.228,459.493,462.758,465.164,468.275,472.399,474.805,477.855,481.979,483.997,486.873,490.998,495.122,499.247,502.123,506.248,510.372,514.497,518.621,522.357,524.849,528.114,530.991,534.032,536.05,540.175,543.217,547.341,550.218,553.483,557.219,560.563,564.688,567.094,569.111,573.236" y="449.978" svg_rhmargin="576.972" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[1] Zhao X, Hu D, Qin J, et al. Effect of bisphosphonates in preventing</text>
  <text x="348.434,350.84,354.106,360.247,364.372,367.248,370.984,373.001,374.625,378.749,382.014,384.891,386.983,391.107,393.984,398.108,400.985,403.391,407.515,410.781,413.186,415.204,418.469,420.089,424.213,428.338,432.462,435.727,437.323,440.199,443.464,446.341,450.465,453.342,457.466,459.872,461.89,466.014,470.139,471.789,475.525,477.931,480.337,483.602,486.479,488.116,492.24,495.117,497.134,503.276,507.012,509.889,513.625,515.213,518.478,521.743,527.885,531.15,535.275,537.681,539.698,542.963,545.938,548.8149999999999,550.417,552.823,556.947,559.353,563.089,565.1060000000001,566.686,570.811,572.828" y="458.935" svg_rhmargin="576.952" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">femoral periprosthetic bone resorption after primary cementless total hip</text>
  <text x="348.434,352.17,355.047,357.453,361.577,364.454,368.578,372.703,374.72,378.536,381.413,383.819,387.555,389.572,392.085,395.82099999999997,398.321,404.463,407.728,410.134,413.87,416.276,420.012,424.136,427.872,429.89,433.626,436.502,438.52,441.396,443.413,445.996,448.873,451.325,457.467,460.344,462.75,466.874,470.999,475.124,477.686,481.422,485.546,488.423,492.159,494.636,500.001,503.266,506.14300000000003,508.695,512.819,516.944,521.068,525.193,527.21,531.334,535.459,537.476,541.601,545.725" y="467.892" svg_rhmargin="547.742" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">arthroplasty: a meta-analysis. J Orthop Surg Res 2015;10:65.</text>
  <text x="336.189,338.595,342.719,345.125,348.434,353.798,357.923,360.799,363.205,366.46999999999997,368.218,371.954,373.971,375.758,381.9,386.024,389.76,391.461,396.825,398.842,400.588,405.1,408.836,412.961,414.703,419.217,421.234,422.98,426.246,428.652,430.407,434.143,436.16,438.177,439.874,443.999,446.875,451.0,453.017,456.282,459.547,462.039,464.057,468.181,472.306,475.183,476.892,481.016,483.422,485.168,489.293,492.169,494.187,500.328,504.064,506.941,510.67699999999996,512.435,516.171,520.295,524.42,526.154,529.031,532.296,536.032,538.049,540.926,542.943,547.068,551.193,552.967,557.092,559.109,563.234,564.986,568.722,572.846" y="476.85" svg_rhmargin="576.97" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[2] Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and</text>
  <text x="348.434,352.559,356.683,359.948,363.21299999999997,365.498,369.234,372.11,374.516,378.641,381.517,385.642,389.766,391.784,395.599,398.476,400.882,404.618,406.881,408.898,413.023,415.328,417.734,421.858,425.123,427.403,432.768,436.892,438.91,441.316,444.581,448.706,450.986,454.721,457.127,460.863,463.269,466.534,469.411,471.734,474.14,477.016,481.141,487.283,489.535,493.659,497.784,501.908,506.033,508.355,510.761,514.886,517.142,521.267,525.392,529.516,533.641,535.658,537.948,540.8249999999999,543.107,547.62,551.745,555.869,559.134,561.418,564.295,568.419,570.436,574.561" y="485.807" svg_rhmargin="576.967" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">knee arthroplasty in the United States from 2005 to 2030. J Bone Joint</text>
  <text x="348.434,352.17,356.295,359.171,362.907,365.441,370.806,376.948,379.444,383.568,387.693,391.817,395.942,397.959,402.083,406.208,408.298,412.422,416.547" y="494.764" svg_rhmargin="420.671" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Surg Am 2007;89:780</text>
  <text x="420.661" y="494.764" svg_rhmargin="424.397" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="424.402,428.527" y="494.764" svg_rhmargin="430.544" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5.</text>
  <text x="336.189,338.595,342.719,345.125,348.434,352.558,356.682,359.559,363.684,366.949,369.826,372.47,378.611,380.628,383.184,387.697,389.715,392.97999999999996,395.599,399.335,404.7,406.717,409.318,413.831,416.708,420.832,424.098,428.222,431.958,436.082,439.818,442.424,446.937,448.954,451.551,454.816,457.222,459.828,463.564,465.581,467.598,470.201,476.425,478.443,482.568,485.167,489.293,491.31,494.187,497.452,501.188,504.064,507.329,509.941,513.677,517.801,521.926,524.51,526.916,531.041,534.306,536.925,541.05,543.927,548.051,551.787,555.911,560.036,562.912,564.93,567.8069999999999,570.428,574.553" y="503.778" svg_rhmargin="576.959" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[3] Furnes O, Lie SA, Espehaug B, et al. Hip disease and the prognosis of</text>
  <text x="348.434,350.84,354.965,357.371,361.107,363.124,366.065,370.189,372.207,376.332,379.217,382.093,385.359,389.483,391.575,395.311,398.576,401.841,407.983,411.248,415.373,417.779,420.655,422.67199999999997,425.588,430.95300000000003,433.865,436.742,440.007,443.743,445.761,449.026,454.779,457.732,461.856,464.262,467.143,471.267,475.391,477.409,481.598,485.723,489.848,492.71,496.834,499.711,501.728,507.87,511.606,514.482,518.218,521.167,523.573,527.698,530.104,533.84,535.8570000000001,538.798,542.922,544.94,549.065,551.95,554.826,558.092,562.216,564.233,567.969,571.235,574.5" y="512.735" svg_rhmargin="576.906" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">total hip replacements. A review of 53,698 primary total hip replace-</text>
  <text x="348.434,354.576,357.841,361.966,364.372,367.249,369.013,371.889,375.154,379.279,383.468,386.345,388.751,392.016,396.141,397.867,400.273,404.398,406.144,408.55,412.675,415.94,417.709,423.851,427.975,430.852,436.605,439.87,443.606,445.624,449.36,453.485,455.294,460.659,463.535,465.941,470.065,472.942,477.067,481.191,483.208,486.944,489.821,492.227,495.96299999999997,497.753,503.118,506.383,510.119,512.136,515.013,517.419,520.768,523.645,525.361,529.485,533.609,537.734,541.858,544.264,548.389,552.513,554.5300000000001,556.313,559.1899999999999,560.905,565.418,569.543,573.667" y="521.692" svg_rhmargin="576.932" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ments reported to the Norwegian Arthroplasty Register 1987-99. J Bone</text>
  <text x="348.434,351.311,355.436,357.453,361.577,363.983,366.518,370.254,374.379,377.255,380.991,383.525,388.038,390.915,393.389,397.514,401.638,405.763,409.887,411.904,416.029,420.153,422.243,426.368,430.493" y="530.649" svg_rhmargin="434.617" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Joint Surg Br 2001;83:579</text>
  <text x="434.607" y="530.649" svg_rhmargin="438.343" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="438.349,442.475,446.6" y="530.649" svg_rhmargin="448.617" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">86.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,352.947,354.965,359.09,361.473,366.376,368.393,370.771,376.137,379.873,383.998,386.362,390.098,395.851,397.868,400.251,405.616,409.352,411.36899999999997,413.743,419.496,424.861,426.878,429.276,432.541,434.947,437.326,441.062,443.079,445.096,447.473,451.986,454.003,456.88,461.005,465.129,469.253,472.13,476.254,480.379,484.503,488.628,492.364,494.77,498.035,500.91200000000003,503.311,505.716,509.841,512.718,515.102,519.226,522.491,525.368,527.385,531.51,534.387,538.511,541.388,543.794,547.918,551.183,553.589,555.607,558.872,561.302,565.427,569.551,573.676" y="539.607" svg_rhmargin="576.941" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[4] Lin T, Yan SG, Cai XZ, et al. Bisphosphonates for periprosthetic bone</text>
  <text x="348.435,350.453,354.577,357.454,360.331,361.927,365.663,368.069,370.475,373.74,376.617,378.197,380.214,384.339,386.356,390.481,392.887,394.524,398.259,401.136,403.542,407.666,410.543,414.667,418.792,420.809,424.545,427.422,429.828,433.564,435.581,437.209,440.945,442.481,448.624,451.889,454.295,458.031,460.437,464.173,468.388,472.124,474.141,477.877,480.754,482.771,485.648,487.209,491.333,493.73900000000003,495.316,499.44,503.565,505.123,508.0,511.736,515.86,519.985,524.17,530.312,532.33,535.595,538.86,542.985,544.578,547.843,551.968,556.092,558.498,561.375,565.499,567.517,569.534,572.799" y="548.564" svg_rhmargin="576.923" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">loss after joint arthroplasty: a meta-analysis of 14 randomized controlled</text>
  <text x="348.435,350.841,353.718,355.735,359.471,361.488,364.365,366.382,368.957,375.098,377.975,380.381,383.646,387.771,391.895,396.019,398.896,403.02,405.897,408.411,410.817,414.942,417.348,419.863,423.987,428.111,432.236,436.36,438.378,442.502,446.627,448.716,452.841,456.965,461.09" y="557.521" svg_rhmargin="465.214" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">trials. Osteoporos Int 2012;23:1823</text>
  <text x="465.222" y="557.521" svg_rhmargin="468.958" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="468.964,473.088,477.212" y="557.521" svg_rhmargin="479.229" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">34.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,352.559,355.436,357.453,360.718,363.124,367.248,369.654,375.019,377.036,381.257,384.992,391.134,395.259,398.135,401.871,405.236,410.989,413.006,416.347,419.224,422.96,426.696,430.431,432.449,436.574,439.873,447.345,452.709,454.726,458.07,460.946,465.071,469.195,472.931,476.19599999999997,479.555,484.92,486.937,490.269,493.535,495.94100000000003,499.283,503.019,505.037,507.054,510.395,515.759,518.636,521.513,525.637,528.902,530.92,534.656,537.062,539.079,543.203,547.328,550.7,554.824,558.09,560.564,566.317,569.582,572.847" y="566.535" svg_rhmargin="576.971" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[5] Prieto-Alhambra D, Javaid MK, Judge A, et al. Association between</text>
  <text x="348.435,352.56,354.577,357.454,361.578,365.703,369.827,372.704,376.828,381.031,385.155,389.28,393.016,395.422,398.687,400.192,404.316,407.193,410.45799999999997,411.983,415.719,419.843,423.968,425.531,427.549,433.691,437.815,439.832,443.568,447.693,450.099,451.665,454.541,458.666,461.542,465.278,467.296,471.032,474.768,476.78499999999997,478.308,482.044,484.45,486.856,490.121,492.998,494.578,498.703,501.579,503.597,509.739,513.474,516.351,520.087,521.619,524.025,528.149,530.555,534.291,536.3080000000001,537.889,541.625,544.502,546.908,551.032,553.909,558.033,562.158,564.175,567.911,570.788,573.194" y="575.492" svg_rhmargin="576.93" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">bisphosphonate use and implant survival after primary total arthroplasty</text>
  <text x="348.435,352.56,354.966,357.903,360.309,364.433,367.698,370.658,374.782,378.907,382.172,385.437,388.345,392.469,395.346,398.266,402.391,404.408,408.532,410.549,413.515,417.64,421.764,425.889,430.013,432.03,435.766,438.172,440.19,444.314,448.439,451.44,455.564,459.3,462.177,465.442,469.567,472.471,475.348,478.613,481.019,483.896,488.02,490.897,495.021,498.286,501.552,503.958,505.975,509.711,512.976,516.008,519.273,523.398,527.522,531.647,534.523,536.929,539.874,542.75,545.156,549.281,553.405,557.141,559.158,562.096,566.609,574.081" y="584.4490000000001" svg_rhmargin="576.958" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">of the knee or hip: population based retrospective cohort study. BMJ</text>
  <text x="348.435,352.56,356.684,360.809,364.933,366.95,371.075,375.199,379.324,381.428,385.552,389.676,393.801,397.925,402.05" y="593.407" svg_rhmargin="404.067" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2011;343:d7222.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,353.799,357.535,361.66,365.395,367.482,370.747,373.624,375.361,380.726,384.85,387.727,390.133,393.398,396.27500000000003,398.037,403.401,405.418,407.22,411.345,415.081,419.205,421.222,424.099,427.364,429.382,431.399,435.524,437.322,441.058,444.323,448.447,452.183,455.06,457.466,459.483,463.219,464.985,467.862,470.739,472.756,474.509,480.733,483.998,486.875,489.752,493.017,495.893,499.62899999999996,501.436,506.801,510.925,515.049,517.926,519.944,523.679,527.804,531.069,534.334,536.129,541.494,543.5110000000001,545.256,548.521,550.9269999999999,552.739,556.475,558.492,560.509,562.262,567.165,570.43,574.554" y="602.364" svg_rhmargin="576.96" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[6] Canales Cortes V, Panisello Sebastiá JJ, Herrera Rodríguez A, et al. Ten-</text>
  <text x="348.435,352.171,355.436,359.172,362.04900000000004,367.37,369.775,373.9,375.917,377.935,382.059,387.812,390.218,394.343,398.468,403.821,407.945,410.351,415.613,419.349,423.474,428.765,432.501,436.626,440.361,442.767,446.892,453.034,455.051,458.316,462.052,464.069,469.411,473.535,477.271,481.396,484.272,488.458,492.583,496.318,500.054,504.179,507.915,510.321,512.338,514.744,518.009,520.415,523.68,527.805,531.541,533.947,537.212,541.337,546.677,549.083,553.207,555.613,559.349,561.3660000000001,566.688,570.813,572.83" y="611.321" svg_rhmargin="576.954" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">year follow-up of an anatomical hydroxyapatite-coated total hip</text>
  <text x="348.435,352.56,355.436,359.561,362.437,364.843,368.968,372.233,375.192,377.209,380.086,382.103,384.602,387.008,391.133,393.539,396.054,402.196,405.073,407.479,411.603,415.728,419.853,422.358,426.483,430.607,434.731,438.856,440.873,444.998,449.122,451.212,455.336" y="620.335" svg_rhmargin="459.46" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">prosthesis. Int Orthop 2006;30:84</text>
  <text x="459.439" y="620.335" svg_rhmargin="463.175" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="463.181,467.306,471.432" y="620.335" svg_rhmargin="473.449" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">90.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,354.188,357.924,359.941,361.958,366.083,367.538,370.415,372.432,373.888,378.401,382.137,386.261,390.386,394.51,397.387,398.831,401.237,403.254,404.727,410.092,413.357,416.622,420.746,424.871,428.607,432.343,433.808,436.214,438.231,439.704,442.969,445.375,446.79,450.526,452.543,454.56,456.031,461.395,465.52,471.662,475.786,479.522,482.398,484.416,487.293,491.417,495.542,497.016,501.141,503.547,505.01,509.134,512.87,516.994,519.871,523.995,528.12,531.856,535.592,539.716,543.452,545.858,547.875,550.281,553.547,555.953,559.316,563.441,567.177,569.583,572.848" y="629.292" svg_rhmargin="576.972" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[7] Gallo J, Landor I, Cechová I, et al. Comparison of hydroxyapatite-coated</text>
  <text x="348.435,351.312,353.718,356.983,363.125,366.002,367.653,369.67,373.795,375.476,377.882,382.007,384.413,388.149,390.166,391.803,395.927,397.945,402.07,403.708,407.444,410.32,412.726,416.851,419.727,423.852,427.976,429.994,433.81,436.686,439.092,442.828,444.467,448.203,450.609,453.015,456.28,459.157,460.794,464.53,466.18,472.322,474.34,478.464,480.481,486.623,490.748,496.89,498.55,502.674,506.798,509.204,512.94,516.206,519.941,522.818,525.6949999999999,527.347,529.753,533.878,535.895,537.913,542.037,547.79,550.196,554.321,558.445,560.4620000000001,562.154,567.519,570.784,573.265" y="638.249" svg_rhmargin="577.001" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">stems in total hip arthroplasty after a minimum 10-years follow-up. Acta</text>
  <text x="348.435,353.8,357.924,359.942,362.819,365.329,371.471,374.347,376.753,380.878,385.002,389.127,391.689,396.592,399.468,403.204,407.329,413.47,417.206,419.612,423.737,425.754,428.311,433.676,436.942,440.207,444.332,446.849,450.974,455.098,459.222,463.347,465.364,469.489,473.613,475.63,479.755,483.879" y="647.207" svg_rhmargin="488.003" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Chir Orthop Traumatol Cech 2008;75:339</text>
  <text x="488.069" y="647.207" svg_rhmargin="491.805" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="491.811,495.936,500.061" y="647.207" svg_rhmargin="502.078" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">46.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,352.947,357.072,360.808,364.932,369.057,372.792,375.669,377.686,379.216,386.688,388.705,390.157,394.67,398.406,400.423,404.159,410.301,416.443,420.179,422.19599999999997,423.66,427.396,429.413,430.916,436.67,440.794,444.53,448.266,450.672,453.07800000000003,454.556,460.309,466.533,468.55,470.031,473.296,475.702,477.174,480.91,482.928,484.945,486.415,490.928,493.334,495.74,499.005,502.27,504.676,506.142,510.267,512.673,514.136,518.26,520.278,523.154,527.279,531.403,535.528,538.404,542.529,546.732,550.856,554.98,558.716,561.122,564.388,567.265,568.726,572.851" y="656.164" svg_rhmargin="576.975" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[8] Bhandari M, Bajammal S, Guyatt GH, et al. Effect of bisphosphonates on</text>
  <text x="348.435,352.56,355.825,358.701,360.719,364.843,367.72,371.844,374.721,377.127,381.251,384.517,387.04,389.057,392.322,393.786,397.91,402.035,406.159,409.424,410.963,417.105,419.122,423.247,426.512,429.388,433.124,435.141,436.699,440.824,444.089,448.214,451.09,453.108,455.513,459.24899999999997,460.792,464.528,466.934,469.34,472.605,475.482,477.005,479.411,483.536,485.942,489.677,491.694,493.218,495.236,499.36,501.378,505.577,507.983,509.488,513.224,516.101,518.507,522.631,525.508,529.632,533.757,535.774,539.51,542.387,544.793,548.528,550.5450000000001,552.117,557.482,558.977,565.12,568.385,570.791,574.527" y="665.121" svg_rhmargin="576.933" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">periprosthetic bone mineral density after total joint arthroplasty. A meta-</text>
  <text x="348.435,352.171,356.296,360.031,362.049,365.785,368.729,370.747,373.623,375.64,378.14,381.017,383.526,388.039,392.163,396.288,399.553,402.063,404.94,409.064,411.082,415.206,417.612,420.091,423.826,427.951,430.828,434.56399999999996,437.097,442.462,448.604,451.1,455.224,459.349,463.473,467.598,469.615,473.74,477.864,479.954,484.078,488.203" y="674.078" svg_rhmargin="492.327" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">analysis. J Bone Joint Surg Am 2005;87:293</text>
  <text x="492.321" y="674.078" svg_rhmargin="496.057" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="496.063,500.187,504.312,508.436" y="674.078" svg_rhmargin="510.453" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">301.</text>
  <text x="336.19,338.596,342.72,345.12600000000003,348.434,353.799,355.817,359.941,364.065,367.801,370.996,375.121,377.138,380.293,385.196,387.213,390.949,394.214,398.339,401.604,405.34,408.525,412.649,414.666,417.822,423.575,427.7,431.824,436.019,440.143,443.879,447.615,450.758,454.883,456.9,460.056,463.321,465.72700000000003,468.899,472.635,474.652,476.669,479.84,484.353,486.759,489.165,492.43,495.695,498.101,501.325,505.45,507.856,511.019,513.896,515.913,518.79,522.055,526.179,529.056,533.181,537.305,541.041,543.447,546.712,549.908,554.032,558.157,561.302,565.427,569.551,573.676" y="683.092" svg_rhmargin="576.941" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[9] Kinov P, Tivchev P, Doukova P, et al. Effect of risedronate on bone</text>
  <text x="348.435,354.577,357.842,360.248,363.984,368.108,372.233,374.341,376.359,379.235,385.377,387.153,390.889,393.295,395.701,398.966,401.843,403.593,405.999,410.123,412.529,416.265,418.282,420.089,424.213,426.231,430.356,432.107,435.843,438.72,441.126,445.25,448.207,452.332,456.456,458.474,462.21,465.086,467.492,471.228,473.245,475.021,478.757,480.52,484.645,487.522,491.646,494.523,498.647,501.913,505.178,507.584,509.601,513.337,516.602,518.445,521.322,525.058,529.182,533.307,537.431,543.573,545.591,548.467,551.732,555.857,557.674,560.551,562.957,567.081,571.206,574.941" y="692.049" svg_rhmargin="576.958" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">metabolism after total hip arthroplasty: a prospective randomised study.</text>
  <text x="348.435,353.8,357.065,359.471,363.207,365.726,371.868,374.744,377.15,381.275,385.399,389.524,392.086,396.599,399.864,401.882,405.618,408.13,412.254,416.378,420.503,424.627,426.645,430.769,434.894,436.911,441.035" y="701.0070000000001" svg_rhmargin="445.159" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Acta Orthop Belg 2006;72:44</text>
  <text x="445.209" y="701.0070000000001" svg_rhmargin="448.945" style="fill:#171615;font-family:BPGNNO+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="448.951,453.076,457.201" y="701.0070000000001" svg_rhmargin="459.218" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">50.</text>
  <text x="332.051,334.457,338.581,342.706,345.112,348.434,352.17,356.295,360.419,362.437,366.561,369.826,373.951,378.075,381.427,384.303,388.039,390.781,396.923,402.676,404.693,407.447,411.183,414.919,416.937,420.202,426.344,430.079,432.956,435.735,443.207,449.349,451.366,454.102,458.615,462.739,466.864,470.129,474.254,477.005,483.229,486.965,488.98199999999997,491.744,495.009,497.415,500.134,503.87,505.888,507.905,510.678,515.58,519.704,522.9689999999999,525.701,528.967,531.372,533.778,537.044,540.309,542.7149999999999,545.486,549.611,552.0169999999999,554.783,560.537,563.802,567.067,571.191,573.209" y="709.9639999999999" svg_rhmargin="576.945" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[10] Sköldenberg OG, Salemyr MO, Bodén HS, et al. The effect of weekly</text>
  <text x="348.435,351.312,353.329,356.206,359.471,363.595,366.472,370.597,374.721,378.537,380.943,384.20799999999997,389.479,393.603,397.728,402.971,407.095,410.361,413.237,415.255,419.379,422.256,426.38,429.257,431.663,435.787,439.052,441.458,443.476,446.741,452.063,456.187,460.312,464.436,467.70099999999996,472.982,475.858,479.124,482.0,486.125,489.001,493.126,495.532,497.549,501.673,505.798,511.077,513.483,517.607,519.624,521.642,525.766,531.52,533.537,537.661,541.3969999999999,546.734,549.14,553.264,555.67,559.406,561.423,566.689,570.813,572.831" y="718.921" svg_rhmargin="576.955" style="fill:#171615;font-family:BPGNFH+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">risedronate on periprosthetic bone resorption following total hip</text>
  <path d=" M 71.88700103759766 766.885009765625 L 577.02099609375 766.885009765625 L 577.02099609375 767.6220092773438 L 71.88700103759766 767.6220092773438 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 71.88700103759766 471.74200439453125 L 577.02099609375 471.74200439453125 L 577.02099609375 472.47900390625 L 71.88700103759766 472.47900390625 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <rect style="stroke:blue;stroke-width:0.3;" x="108.454" y="40.202" height="268.951" width="432.0" title="6"/>
  <text x="108.454" y="40.202" class="image" id="image.6.1" width="432" height="268">image.6.1.108_540.40_309</text>
  <text svg_rhmargin="133.476" x="103.295,107.651,109.438,113.795,118.069,120.633,124.758,127.334,131.459,133.476" y="320.151" style="fill:#171615;font-family:BPGNLM+AdvOTf94803d4;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Figure 6. </text>
  <text svg_rhmargin="435.541" x="137.196,141.164,145.288,147.619,151.43,155.009,157.183,159.701,163.975,165.298,169.422,171.596,174.1,177.911,182.035,188.177,192.524,196.335,198.666,199.989,203.956,208.081,210.551,212.726,216.693,220.50400000000002,223.023,226.602,230.413,232.744,236.712,242.85399999999998,245.416,250.624,254.748,259.022,261.742,263.37100000000004,265.88,270.155,273.965,276.14,281.661,285.472,289.283,293.25100000000003,295.812,298.143,299.466,303.045,306.855,311.129,313.461,317.585,321.552,325.363,327.537,331.34799999999996,333.906,338.031,340.362,344.486,348.454,352.728,355.221,359.032,362.999,367.273,369.79,373.601,377.725,381.693,383.867,386.198,390.323,391.64599999999996,394.166,398.291,400.622,404.746,408.714,412.988,415.005,417.522,422.794,426.918,431.192,433.912,435.541" y="320.151" style="fill:#171615;font-family:BPGNEB+AdvOT6e5d2ec0;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Forest plot comparing the serum NTX-I between risedronate group and control group. NTX-I </text>
  <text x="436.476" y="320.151" svg_rhmargin="441.534" style="fill:#171615;font-family:BPGNEH+AdvOTb0c9bf5d;font-size:7.47px;font-style:NORMAL;font-weight:normal;">=</text>
  <text x="442.486,447.694,450.413,452.588,456.398,457.721,461.845,466.119,469.93,474.204,476.378,477.802,482.076,485.887,488.403,492.527,494.395,496.85,499.024,502.446,506.72,510.531,513.063,514.692,517.201,521.012,525.137,526.459,527.782,531.592,535.717,539.527,543.495" y="320.151" svg_rhmargin="545.512" style="fill:#171615;font-family:BPGNEB+AdvOT6e5d2ec0;font-size:7.47px;font-style:NORMAL;font-weight:normal;">N-telopeptide of type I collagen.</text>
  <text svg_rhmargin="179.735" x="71.887,76.868,81.1,83.735,87.8,90.119,92.749,96.814,98.225,100.377,103.01,109.562,113.627,118.186,119.596,123.661,125.072,129.304,133.369,136.004,137.909,142.309,146.708,151.108,155.508,157.413,159.984,164.384,168.784,170.935,175.335,179.734" y="9.870999999999981" style="fill:#171615;font-family:BPGNEB+AdvOT6e5d2ec0;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Su et al. Medicine (2018) 97:51 </text>
  <text x="542.723,549.944,554.503,559.317,561.31,565.869,567.861,572.508" y="9.870999999999981" svg_rhmargin="577.067" style="fill:#171615;font-family:BPGNEA+AdvOT34fe1490.B;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Medicine</text>
  <text x="322.243" y="739.625" svg_rhmargin="326.643" style="fill:#171615;font-family:BPGNLM+AdvOTf94803d4;font-size:7.97px;font-style:NORMAL;font-weight:normal;">6</text>
 </g>
</svg>
